HomeBUSINESS
BUSINESS

With 2 Players Closing in on Suglat, SGLT2 Inhibitors Entering Triangular Battle
(Feb.8.2018)

By Reiji Anasako

As the Japanese SGLT2 inhibitor market starts to get on a growth track, competition in the crowded space is expected to heat up particularly among the top three products. First-in-class Suglat (ipragliflozin) is now closely trailed by Forxiga (dapagliflozin), with last-to-market Jardiance (empagliflozin) also gaining traction in the newly diagnosed patient segment ...
(LOG IN FOR FULL STORY)

Notice

 The next ebook update will be provided on August 20.

News Calendar